Lilly To Provide Free Access to Drug Discovery Platform Under New Collaborative Initiative | GenomeWeb

NEW YORK (GenomeWeb News) - Eli Lilly & Co. said today that it will provide free access to its drug discovery technology to potential collaborators who want to evaluate the therapeutic potential of their compounds.

Under the new program, called the Phenotypic Drug Discovery Initiative, or PD2, Lilly said it will provide free, confidential access to its drug discovery assays via a secure web portal in a move intended to provide "a more convenient point of entry for global external researchers into Lilly's drug discovery and development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.